FDA Grants AP Status for Lidocaine Hydrochloride 0.4% in Dextrose 5%
The FDA has granted Abbreviated Approval (AP) status for Lidocaine Hydrochloride 0.4% in Dextrose 5% submitted by Hospira.
Asset / Drug
Drug and asset intelligence for Hospira with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.